Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-021941
Filing Date
2025-11-12
Accepted
2025-11-12 16:26:01
Documents
65
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 2081820
2 EX-31.1 ex31-1.htm EX-31.1 18740
3 EX-31.2 ex31-2.htm EX-31.2 18809
4 EX-32.1 ex32-1.htm EX-32.1 7507
5 EX-32.2 ex32-2.htm EX-32.2 7523
6 GRAPHIC form10-q_001.jpg GRAPHIC 102854
7 GRAPHIC form10-q_002.jpg GRAPHIC 103392
  Complete submission text file 0001493152-25-021941.txt   10271380

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE lixt-20250930.xsd EX-101.SCH 58600
9 XBRL CALCULATION FILE lixt-20250930_cal.xml EX-101.CAL 40972
10 XBRL DEFINITION FILE lixt-20250930_def.xml EX-101.DEF 324017
11 XBRL LABEL FILE lixt-20250930_lab.xml EX-101.LAB 509301
12 XBRL PRESENTATION FILE lixt-20250930_pre.xml EX-101.PRE 403739
67 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1779915
Mailing Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432
Business Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39717 | Film No.: 251473206
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)